🇺🇸 Exparel + Bupivacaine in United States

24 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pain — 4 reports (16.67%)
  2. Bradycardia — 3 reports (12.5%)
  3. Post Procedural Haematoma — 3 reports (12.5%)
  4. Arrhythmia — 2 reports (8.33%)
  5. Blister — 2 reports (8.33%)
  6. Breast Haematoma — 2 reports (8.33%)
  7. Ecchymosis — 2 reports (8.33%)
  8. Hypoaesthesia — 2 reports (8.33%)
  9. Hypotension — 2 reports (8.33%)
  10. Nausea — 2 reports (8.33%)

Source database →

Other Anesthesia / Pain Management approved in United States

Frequently asked questions

Is Exparel + Bupivacaine approved in United States?

Exparel + Bupivacaine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Exparel + Bupivacaine in United States?

Pacira Pharmaceuticals, Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.